R01AA029594
Project Grant
Overview
Grant Description
Maternal Mediators of Fetal Growth Restriction Linked to Prenatal Alcohol Exposure - Project Summary/Abstract
Prenatal alcohol exposure (PAE) is a common cause of fetal growth restriction (FGR), which is a known risk factor for brain disability. Our previous studies identified extracellular maternal miRNAs as a causal link between PAE and FGR. These studies in pregnant women in Ukraine resulted in the discovery of 11 miRNAs (HEAmiRNAs) that were elevated in plasma of heavy alcohol-exposed mothers who subsequently delivered growth-restricted, alcohol-affected infants (HEA), but not in exposed mothers who delivered infants that were apparently unaffected (HEUA), or unexposed (UE) mothers. Maternal HEAmiRNAs collectively explained 24-31% of the variance in infant height, weight, and head circumference at birth, and in rodents, non-human primates, and in human trophoblast cell lines, explained PAE inhibition of placental trophoblast epithelial-mesenchymal transition (EMT) and FGR.
Studies in this proposal test an innovative hypothesis that two candidate cytokines, also identified in the Ukraine cohort, and extracellular miRNAs, control fetal growth in response to PAE, and that these may be manipulated to overcome FGR. In Aim 1, we test the hypothesis that two PAE-sensitive cytokines, C-reactive protein and sFLT1, control HEAmiRNA transfer between maternal circulation and trophoblasts, as a means to inhibit the growth of chorionic villi, leading to FGR. Aim 2 is based on initial studies that showed 3 HEAmiRNAs, which were elevated in both preeclampsia and FGR, promoted EMT gene expression in trophoblasts. We plan to test the hypotheses that cytokines, and sub-groups of birth outcome-defined HEAmiRNAs may be manipulated to overcome FGR. Studies in Aims 1 and 2 will use cell culture and mouse models, with ultrasound imaging and transcriptomic studies, to assess the role of cytokines and HEAmiRNAs in PAE-mediated inhibition of placental and fetal growth.
In Aim 3, we will assess associations between HEAmiRNAs, and other conditions linked to defects in placental development and function (preeclampsia, pre-term birth, spontaneous abortion, FGR), in samples from pregnant women recruited in the San Diego region with and without evidence of placental dysfunction, including PAE. We will additionally investigate the distribution of HEAmiRNAs in lipoprotein particles (LPPs) and extracellular vesicles (EVs) to determine whether pregnancy and/or placental dysfunction is associated with redistribution of HEAmiRNAs among extracellular compartments, possibly influencing their endocrine function and target tissue distribution.
The proposed studies, led by qualified investigators with complementary skills, meet a significant need for mechanism-centered diagnoses and intervention for pregnancy complications due to PAE and other etiologies.
Prenatal alcohol exposure (PAE) is a common cause of fetal growth restriction (FGR), which is a known risk factor for brain disability. Our previous studies identified extracellular maternal miRNAs as a causal link between PAE and FGR. These studies in pregnant women in Ukraine resulted in the discovery of 11 miRNAs (HEAmiRNAs) that were elevated in plasma of heavy alcohol-exposed mothers who subsequently delivered growth-restricted, alcohol-affected infants (HEA), but not in exposed mothers who delivered infants that were apparently unaffected (HEUA), or unexposed (UE) mothers. Maternal HEAmiRNAs collectively explained 24-31% of the variance in infant height, weight, and head circumference at birth, and in rodents, non-human primates, and in human trophoblast cell lines, explained PAE inhibition of placental trophoblast epithelial-mesenchymal transition (EMT) and FGR.
Studies in this proposal test an innovative hypothesis that two candidate cytokines, also identified in the Ukraine cohort, and extracellular miRNAs, control fetal growth in response to PAE, and that these may be manipulated to overcome FGR. In Aim 1, we test the hypothesis that two PAE-sensitive cytokines, C-reactive protein and sFLT1, control HEAmiRNA transfer between maternal circulation and trophoblasts, as a means to inhibit the growth of chorionic villi, leading to FGR. Aim 2 is based on initial studies that showed 3 HEAmiRNAs, which were elevated in both preeclampsia and FGR, promoted EMT gene expression in trophoblasts. We plan to test the hypotheses that cytokines, and sub-groups of birth outcome-defined HEAmiRNAs may be manipulated to overcome FGR. Studies in Aims 1 and 2 will use cell culture and mouse models, with ultrasound imaging and transcriptomic studies, to assess the role of cytokines and HEAmiRNAs in PAE-mediated inhibition of placental and fetal growth.
In Aim 3, we will assess associations between HEAmiRNAs, and other conditions linked to defects in placental development and function (preeclampsia, pre-term birth, spontaneous abortion, FGR), in samples from pregnant women recruited in the San Diego region with and without evidence of placental dysfunction, including PAE. We will additionally investigate the distribution of HEAmiRNAs in lipoprotein particles (LPPs) and extracellular vesicles (EVs) to determine whether pregnancy and/or placental dysfunction is associated with redistribution of HEAmiRNAs among extracellular compartments, possibly influencing their endocrine function and target tissue distribution.
The proposed studies, led by qualified investigators with complementary skills, meet a significant need for mechanism-centered diagnoses and intervention for pregnancy complications due to PAE and other etiologies.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
La Jolla,
California
920930828
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 380% from $662,988 to $3,182,128.
San Diego University Of California was awarded
Maternal Mediators of Fetal Growth Restriction Due to Prenatal Alcohol Exposure
Project Grant R01AA029594
worth $3,182,128
from National Institute on Alcohol Abuse and Alcoholism in September 2022 with work to be completed primarily in La Jolla California United States.
The grant
has a duration of 4 years 9 months and
was awarded through assistance program 93.273 Alcohol Research Programs.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 7/6/26
Period of Performance
9/20/22
Start Date
6/30/27
End Date
Funding Split
$3.2M
Federal Obligation
$0.0
Non-Federal Obligation
$3.2M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R01AA029594
Transaction History
Modifications to R01AA029594
Additional Detail
Award ID FAIN
R01AA029594
SAI Number
R01AA029594-4013586749
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75N500 NIH National Institute on Alcohol Abuse and Alcoholism
Funding Office
75N500 NIH National Institute on Alcohol Abuse and Alcoholism
Awardee UEI
UYTTZT6G9DT1
Awardee CAGE
50854
Performance District
CA-50
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Health and Human Services (075-0894) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,310,574 | 100% |
Modified: 7/6/26